Medicare AdvantageCoverageMedium impact
MA08.011h, Erythropoiesis Stimulating Agents (ESAs)
Independence Blue Cross·Nephrology, Oncology, Hematology·Medical Policy
Effective date
Nov 17, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.011h for Erythropoiesis Stimulating Agents (ESAs) has been updated with changes to medical necessity criteria and medical coding requirements. This affects billing and coverage determinations for ESA treatments used primarily in chronic kidney disease and certain cancer patients.
Action Required
By November 17, 2025: Billing team must review updated medical necessity criteria for ESA billing on Medicare Advantage plans. Update prior authorization workflows and documentation requirements for ESA treatments. Verify coding guidelines have been updated in billing system to align with new policy requirements.